Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma

Fig. 4

Antioxidant NAC aggravates chemoresistance via stabilizing BACH1 in BTZ-resistant MCL cells. a Cell viability was measured in resistant cells treated with BTZ (20 nM) with or without NAC pretreatment (100 μM) for 24 h. Data are normalized to single BTZ-treated cells and shown as the mean ± SD from three independent experiments. **p < 0.01; ***p < 0.001 (vs single BTZ-treated group). BACH1 protein levels (b) and BACH1 mRNA levels (c) in REC-1 and BACH2KD Jeko cells treated with BTZ (20 nM) with or without NAC pretreatment (100 μM) for 24 h. Actin was used as a loading control for immunoblotting. Each value from real-time RT-PCR was normalized to ACTB and is presented as the mean ± SD from three independent experiments. N.S, not significant (vs single BTZ-treated group). d REC-1 and BACH2KD Jeko cells were treated with BTZ (20 nM) in the presence or absence of NAC (100 μM) for 16 h, followed by addition of CHX (50 μg/mL) at the indicated time. BACH1 proteins were measured using immunoblotting with Actin as a loading control. e The relative half-life (t1/2) of BACH1 (50% of degradation, black arrow) is indicated in the diagram. Blue dotted lines represent t1/2 of BACH1 in REC-1 and BACH2KD Jeko cells after single-BTZ treatment, whereas red dotted lines represent t1/2 of BACH1 in REC-1 and BACH2KD Jeko cells treated with BTZ and NAC. f BACH1 mRNA levels in patients with MCL (n = 8) compared to patients with other subtypes including diffuse large B cell lymphoma (DLBCL, n = 60), Burkitt lymphoma (BL, n = 17), follicular lymphoma (FL, n = 6) and primary effusion lymphoma (PEL, n = 9). Data are shown as the mean ± SEM. N.S, not significant. g Correlation analyses of BACH1 and CCND1 expression values based on microarray data in patients with MCL (n = 57). R value and p value are indicated

Back to article page